Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature

R. Rossero, David Asmuth, J. J. Grady, D. S. McKinsey, S. Green, L. Andron, Richard B Pollard

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The safety and efficacy of hydroxyurea with didanosine in combination with stavudine in nucleoside reverse-transcriptase inhibitor (NRTI)-experienced patients was investigated. Entry criteria included HIV-1 infected, NRTI-experienced adults, with CD4+ counts 50-550 cells/mm3 and viral loads ≥12,500 copies/mL. Subjects were treated with didanosine 200 mg twice a day (BID), stavudine 40 mg BID, and hydroxyurea 1000 mg daily for 16 weeks. Thirty-one HIV-1 subjects with mean bDNA viral load 1 × 105 log10 copies/mL and mean CD4+ T-cell counts of 231 cells/mm3 were enrolled. A 1.3 log10 decrease in mean viral load was seen at 12 weeks of therapy. Prior didanosine use resulted in a more rapid response to therapy compared with prior zidovudine use. Side effects consisting of neutropenia, pancreatitis, and peripheral neuropathy occurred in four subjects and resolved upon withdrawal of therapy. This non-randomized study in subjects with a mean CD4+ T-cell count of 230 cells/mm3 demonstrates the antiviral activity of hydroxyurea+didanosine and stavudine. Toxicities related to therapy need to be followed closely. The results support the need for a randomized, prospective study to determine the safety and efficacy of hydroxyurea plus didanosine in antiretroviral-experienced patients with CD4+ cell counts below 300 cells/mm3.

Original languageEnglish (US)
Pages (from-to)350-355
Number of pages6
JournalInternational Journal of STD and AIDS
Volume14
Issue number5
DOIs
StatePublished - May 1 2003

Fingerprint

Stavudine
Didanosine
Hydroxyurea
CD4 Lymphocyte Count
HIV
Viral Load
Reverse Transcriptase Inhibitors
Nucleosides
HIV-1
T-Lymphocytes
Safety
Zidovudine
Peripheral Nervous System Diseases
Therapeutics
Neutropenia
Pancreatitis
Antiviral Agents
Prospective Studies

Keywords

  • Antiretroviral therapy
  • Didanosine
  • Hydroxyurea
  • Review

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Cite this

Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature. / Rossero, R.; Asmuth, David; Grady, J. J.; McKinsey, D. S.; Green, S.; Andron, L.; Pollard, Richard B.

In: International Journal of STD and AIDS, Vol. 14, No. 5, 01.05.2003, p. 350-355.

Research output: Contribution to journalArticle

@article{40a70a44736943ea8273d77cf61b246a,
title = "Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature",
abstract = "The safety and efficacy of hydroxyurea with didanosine in combination with stavudine in nucleoside reverse-transcriptase inhibitor (NRTI)-experienced patients was investigated. Entry criteria included HIV-1 infected, NRTI-experienced adults, with CD4+ counts 50-550 cells/mm3 and viral loads ≥12,500 copies/mL. Subjects were treated with didanosine 200 mg twice a day (BID), stavudine 40 mg BID, and hydroxyurea 1000 mg daily for 16 weeks. Thirty-one HIV-1 subjects with mean bDNA viral load 1 × 105 log10 copies/mL and mean CD4+ T-cell counts of 231 cells/mm3 were enrolled. A 1.3 log10 decrease in mean viral load was seen at 12 weeks of therapy. Prior didanosine use resulted in a more rapid response to therapy compared with prior zidovudine use. Side effects consisting of neutropenia, pancreatitis, and peripheral neuropathy occurred in four subjects and resolved upon withdrawal of therapy. This non-randomized study in subjects with a mean CD4+ T-cell count of 230 cells/mm3 demonstrates the antiviral activity of hydroxyurea+didanosine and stavudine. Toxicities related to therapy need to be followed closely. The results support the need for a randomized, prospective study to determine the safety and efficacy of hydroxyurea plus didanosine in antiretroviral-experienced patients with CD4+ cell counts below 300 cells/mm3.",
keywords = "Antiretroviral therapy, Didanosine, Hydroxyurea, Review",
author = "R. Rossero and David Asmuth and Grady, {J. J.} and McKinsey, {D. S.} and S. Green and L. Andron and Pollard, {Richard B}",
year = "2003",
month = "5",
day = "1",
doi = "10.1258/095646203321605576",
language = "English (US)",
volume = "14",
pages = "350--355",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature

AU - Rossero, R.

AU - Asmuth, David

AU - Grady, J. J.

AU - McKinsey, D. S.

AU - Green, S.

AU - Andron, L.

AU - Pollard, Richard B

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The safety and efficacy of hydroxyurea with didanosine in combination with stavudine in nucleoside reverse-transcriptase inhibitor (NRTI)-experienced patients was investigated. Entry criteria included HIV-1 infected, NRTI-experienced adults, with CD4+ counts 50-550 cells/mm3 and viral loads ≥12,500 copies/mL. Subjects were treated with didanosine 200 mg twice a day (BID), stavudine 40 mg BID, and hydroxyurea 1000 mg daily for 16 weeks. Thirty-one HIV-1 subjects with mean bDNA viral load 1 × 105 log10 copies/mL and mean CD4+ T-cell counts of 231 cells/mm3 were enrolled. A 1.3 log10 decrease in mean viral load was seen at 12 weeks of therapy. Prior didanosine use resulted in a more rapid response to therapy compared with prior zidovudine use. Side effects consisting of neutropenia, pancreatitis, and peripheral neuropathy occurred in four subjects and resolved upon withdrawal of therapy. This non-randomized study in subjects with a mean CD4+ T-cell count of 230 cells/mm3 demonstrates the antiviral activity of hydroxyurea+didanosine and stavudine. Toxicities related to therapy need to be followed closely. The results support the need for a randomized, prospective study to determine the safety and efficacy of hydroxyurea plus didanosine in antiretroviral-experienced patients with CD4+ cell counts below 300 cells/mm3.

AB - The safety and efficacy of hydroxyurea with didanosine in combination with stavudine in nucleoside reverse-transcriptase inhibitor (NRTI)-experienced patients was investigated. Entry criteria included HIV-1 infected, NRTI-experienced adults, with CD4+ counts 50-550 cells/mm3 and viral loads ≥12,500 copies/mL. Subjects were treated with didanosine 200 mg twice a day (BID), stavudine 40 mg BID, and hydroxyurea 1000 mg daily for 16 weeks. Thirty-one HIV-1 subjects with mean bDNA viral load 1 × 105 log10 copies/mL and mean CD4+ T-cell counts of 231 cells/mm3 were enrolled. A 1.3 log10 decrease in mean viral load was seen at 12 weeks of therapy. Prior didanosine use resulted in a more rapid response to therapy compared with prior zidovudine use. Side effects consisting of neutropenia, pancreatitis, and peripheral neuropathy occurred in four subjects and resolved upon withdrawal of therapy. This non-randomized study in subjects with a mean CD4+ T-cell count of 230 cells/mm3 demonstrates the antiviral activity of hydroxyurea+didanosine and stavudine. Toxicities related to therapy need to be followed closely. The results support the need for a randomized, prospective study to determine the safety and efficacy of hydroxyurea plus didanosine in antiretroviral-experienced patients with CD4+ cell counts below 300 cells/mm3.

KW - Antiretroviral therapy

KW - Didanosine

KW - Hydroxyurea

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=0038475908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038475908&partnerID=8YFLogxK

U2 - 10.1258/095646203321605576

DO - 10.1258/095646203321605576

M3 - Article

C2 - 12803944

AN - SCOPUS:0038475908

VL - 14

SP - 350

EP - 355

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 5

ER -